Feedback / Questions
Lunsumio (mosunetuzumab-axgb) - Roche
Lunsumio: Regulatory submissions in US/EU for 2L follicular lymphoma in 2027
(Roche)
-
Oct 1, 2026 -
Pharma Day 2026
EMA filing • FDA filing
•
Follicular Lymphoma • Hematological Malignancies • Oncology
https://assets.roche.com/f/176343/x/51deda2587/20260928_final_pharma-day-2026-publish-1.pdf
Oct 1, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious